New Formulation and Data for Otenaproxesul
January 18, 2024 - 11am ET | Virtual Event (recording available following the live event)
Learn about the benefits of otenaproxesul’s new formulation, dive into Antibe’s recently released data and Phase II planning, and explore the future of pain management.
As the opioid crisis drives prescribers, patients, payors and policymakers toward non-addictive alternatives, nonsteroidal anti-inflammatory drugs (NSAIDs) are increasingly employed to treat acute pain. However, today’s NSAIDs can cause gastrointestinal ulcers and bleeding, especially at the higher doses often employed in acute indications. Formulated to promote rapid onset of action, otenaproxesul is a non-opioid oral painkiller. Its Phase II trial is set to initiate in calendar Q1 2024, with top-line data expected in Q3 2024. With no novel oral pain drugs introduced since the late 1990s, there is urgent demand for alternatives to opioids to treat post-operative pain, acute musculoskeletal pain, dental pain and a range of other acute pain indications.
Dr. Bhargava of Allele Capital will join Dan Legault, our Chief Executive Officer of Antibe Therapeutics, and Dr. Joe Stauffer, our Chief Medical Officer. Tune in as they share insights on otenaproxesul’s transformative potential in acute pain management.
Click here to watch the recording of the live event.